Antibodies that bind to sugars on the surface of cancer cells, rather than to proteins, have not yielded satisfactory results so far due to their low binding affinity. However, scientists at the ...

The threat of tariffs on imports of branded drugs is about to be realized after U.S. President Donald Trump announced a 100% ...

Phase Scientific International Ltd. launched China’s largest clinical study for urine-based cervical cancer screening. If successful, the blood-based test could be the first non-invasive test for HPV.

Rakuten Medical Inc. is advancing a pipeline of solid tumor therapeutics built on its Alluminox platform worldwide, having ...

Tiziana Life Sciences Ltd. has announced plans to advance its second asset, a fully human anti-IL-6 receptor (IL-6R) monoclonal antibody, TZLS-501.

Is there a link between cellular senescence and multiple sclerosis (MS) progression? Several presentations at this year’s ...

Eli Lilly and Co.’s oral selective estrogen receptor degrader (SERD) imlunestrant has been approved by the U.S. FDA for ...

Youthbio Therapeutics Inc. has held a successful INTERACT meeting with the FDA for its lead Alzheimer’s candidate, YB-002.

Boehringer Ingelheim Pharma GmbH & Co KG has advanced a novel T-cell engager resulting from a collaboration with Numab ...

The U.S. FDA released a trio of draft guidances to help sponsors in developing and monitoring cell and gene therapies, as ...

Coronary artery bypass graft (CABG) surgery remains the gold standard treatment for patients with severe atherosclerosis, but ...

Biopharma happenings, including deals and partnerships, and other news in brief: Cidara, Evaxion, Gossamer, Lunia Bioworks, Merck, Qurient, Respira, Synaffix, Tiziana, Verona.